Health-care companies slipped after a disappointing result in one key trial.
Biogen shares tumbled after a trial of the biotech firm's experimental drug for Alzheimer's disease failed to show that higher doses produced greater benefits for patients. The treatment showed promise at lower doses, a hopeful sign after decades of failures for Alzheimer's disease drugs across the industry.
State laws in California and Oregon restricting private-equity involvement in the medical sector are starting to bite, with California Attorney General Rob Bonta penalizing Aspen Dental Management, which is backed by asset managers Leonard Green & Partners and Ares Management.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
05-14-26 1747ET
